Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis

Introduction: China has ~6 million patients with active epilepsy every year, around 60% of whom suffer from partial-onset seizures. Perampanel (PER) is a novel anti-epileptic drug for partial-onset seizures. PER has been included in the latest Chinese National Reimbursement Drug List (NRDL) in 2020....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Public Health
Päätekijät: Zhang, Donger, Li, Xia, Ding, Jing, Ke, Xiatong, Ding, Wenpei, Ren, Yinan, Xu, He, Li, Hongchao, Ma, Aixia, Tang, Wenxi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2021
Aiheet:
Public Health
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290415/
https://ncbi.nlm.nih.gov/pubmed/34295868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpubh.2021.670108
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia